Abstract
Glycosaminoglycans (GAGs) including chondroitin sulfate (CS) and chondroitin sulfate/dermatan sulfate (CS/DS) copolymers are anionic straight chain polysaccharides. They are galactosamine containing GAGs (galactosaminoglycans) having wide range of applications in pharmaceutical, cosmetic and food industries. This article reviews techniques to isolate and characterize these galactosaminoglycans from animal and poultry tissues. Patent based information is also discussed. Cartilaginous tissues are the major source of CS consisting entirely of D-glucuronosyl-N-acetylgalactosamine repeating disaccharide units, in which the galactosamine is sulfated at C4 or C6. In contrast, most galactosaminoglycans in non-cartilaginous connective tissues (e.g. skin and tendon) are CS/DS copolymers comprised of varying proportions of D-glucuronosyl-N-acetylgalactosamine and L-iduronosyl-N-acetylgalactosamine. Tissues are digested with proteinase (e.g. papain) to liberate GAGs, which are fractionated to isolate and purify galactosaminoglycans. Common techniques used for fractionation of GAGs include: precipitation with different concentrations of ethanol; solubilization of GAG precipitated as GAG-quarternary ammonium compound complexes with different concentrations of NaCl; anion exchange chromatography and gel filtration chromatography. Purified galactosaminoglycans are examined by various methods including chondroitinase digestion, high performance liquid chromatography and electrophoresis. Histological methods are used to localize galactosaminoglycans in tissues. The patent information on the CS hydrolase and ultraviolet irradiation may be useful for the preparation of CS oligosaccharide.
Keywords: Chondroitin sulfate, dermatan sulfate, chondroitin sulfate/dermatan sulfate copolymers, glycosaminoglycan, galactosaminoglycan, cartilage, anion exchange chromatography
Recent Patents on Food, Nutrition & Agriculture
Title: Extraction, Isolation and Analysis of Chondroitin Sulfate Glycosaminoglycans
Volume: 2 Issue: 1
Author(s): Takuo Nakano, Mirko Betti and Zeb Pietrasik
Affiliation:
Keywords: Chondroitin sulfate, dermatan sulfate, chondroitin sulfate/dermatan sulfate copolymers, glycosaminoglycan, galactosaminoglycan, cartilage, anion exchange chromatography
Abstract: Glycosaminoglycans (GAGs) including chondroitin sulfate (CS) and chondroitin sulfate/dermatan sulfate (CS/DS) copolymers are anionic straight chain polysaccharides. They are galactosamine containing GAGs (galactosaminoglycans) having wide range of applications in pharmaceutical, cosmetic and food industries. This article reviews techniques to isolate and characterize these galactosaminoglycans from animal and poultry tissues. Patent based information is also discussed. Cartilaginous tissues are the major source of CS consisting entirely of D-glucuronosyl-N-acetylgalactosamine repeating disaccharide units, in which the galactosamine is sulfated at C4 or C6. In contrast, most galactosaminoglycans in non-cartilaginous connective tissues (e.g. skin and tendon) are CS/DS copolymers comprised of varying proportions of D-glucuronosyl-N-acetylgalactosamine and L-iduronosyl-N-acetylgalactosamine. Tissues are digested with proteinase (e.g. papain) to liberate GAGs, which are fractionated to isolate and purify galactosaminoglycans. Common techniques used for fractionation of GAGs include: precipitation with different concentrations of ethanol; solubilization of GAG precipitated as GAG-quarternary ammonium compound complexes with different concentrations of NaCl; anion exchange chromatography and gel filtration chromatography. Purified galactosaminoglycans are examined by various methods including chondroitinase digestion, high performance liquid chromatography and electrophoresis. Histological methods are used to localize galactosaminoglycans in tissues. The patent information on the CS hydrolase and ultraviolet irradiation may be useful for the preparation of CS oligosaccharide.
Export Options
About this article
Cite this article as:
Nakano Takuo, Betti Mirko and Pietrasik Zeb, Extraction, Isolation and Analysis of Chondroitin Sulfate Glycosaminoglycans, Recent Patents on Food, Nutrition & Agriculture 2010; 2 (1) . https://dx.doi.org/10.2174/2212798411002010061
DOI https://dx.doi.org/10.2174/2212798411002010061 |
Print ISSN 2212-7984 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1429 |
Related Articles
-
The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine
Current Molecular Medicine Applications of Nuclear Technique to Biological Sciences Labelled Compounds, Radioactive Tracers, and X-Ray Tomography
Current Topics in Medicinal Chemistry Conjugates of Natural Compounds with Nitroxyl Radicals as a Basis for Creation of Pharmacological Agents of New Generation
Current Medicinal Chemistry Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy
Current Diabetes Reviews Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology
Current Neuropharmacology Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Cancer Drug Targets Assembly of Quinoline, Triazole and Oxime Ether in a Single Molecular Entity: A Greener and One-pot Synthesis of Novel Oximes as Potential Cytotoxic Agents
Letters in Drug Design & Discovery AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies
Current Neuropharmacology Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Small Non-Coding RNAs as Biomarkers
Recent Patents on Biomarkers Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Oil-based Formulation as a Sustained-Released Injection for a Novel Synthetic Peptide
Current Pharmaceutical Biotechnology Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors
Clinical Cancer Drugs